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Abstract: 
 
B-cell activating factor from the TNF family (BAFF) and APRIL are crucial 
survival factors for peripheral B cells. An excess of BAFF leads to the 
development of autoimmune disorders in animal models, and high levels of 
BAFF have been detected in the serum of patients with various autoimmune 
conditions. We discuss that in mice, autoimmunity induced by BAFF seems to be 
linked to T cell-independent B cell activation rather than to a severe breakdown 
of B-cell tolerance. We also outline the mechanisms of BAFF signalling, the 
impact of ligand oligomerization on receptor activation, and the progress of 
BAFF-depleting agents in the clinic. 
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Immune cells produced in the bone marrow undergo a process of quality control, 
known as immune tolerance, that occurs throughout the life of B and T cells and that 
carefully selects useful protective immune cells while eliminating or neutralizing 
potentially harmful self-reactive cells 
1
. The elimination or reprogramming of self-
reactive B cells through B-cell receptor (BCR) editing [G] takes place during B-cell 
development in the bone marrow, during B-cell maturation in the spleen and most 
probably after activation, following affinity maturation in a germinal centre 
2
. 
The nature of BCR engagement 
3
 and the availability of survival cytokines, 
such as interleukin-7 and B-cell activating factor from the TNF family (BAFF), are 
key determinants deciding the life or death of developing B cells during the 
establishment of tolerance 
1
. Thus, the balance between antigen receptor-driven 
stimuli and signals from survival cytokines controls the quality of most emerging 
immune cells.  It was therefore tempting to assume that the autoimmune symptoms 
that are observed in BAFF over-expressing mice are due to the rescue of auto-reactive 
B cells from deletion. This Review describes that this is unlikely to be the only 
possible explanation for the association between BAFF and autoimmunity; new 
evidence implicates BAFF in the pathogenic activation of T cell-independent, low-
affinity self-reactive B cells. At a time when BAFF antagonists are being actively 
tested in clinical trials for autoimmunity and lymphomas, this Review also 
summarizes our knowledge of how BAFF and its closely related homologue APRIL 
(a proliferation-inducing ligand) activate their receptors and transmit survival and 
growth signals to B cells.   
 
Ligands in the BAFF system 
The tumour-necrosis factor (TNF)-family ligands BAFF (also known as TNFSF13B, 
BLyS or TALL-1) and APRIL (also known as TNFSF13) are homotrimeric type II 
transmembrane proteins. A membrane-bound form of APRIL, TWE-PRIL, is 
generated by trans-splicing [G] of the adjacent TWEAK (TNF-related weak inducer 
of apoptosis) and APRIL genes 4, but little is known about the physiological function 
of TWE-PRIL.  
BAFF and APRIL are proteolytically processed at furin consensus sequences 
to produce soluble cytokines (FIG 1). The processing of membrane-bound APRIL is 
very efficient 4, explaining why epitopes located before and after the processing site 
fail to co-localize by immunohistochemistry 5, 6.  BAFF, however, can also be found 
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in a membrane-bound form. In myeloid cells, BAFF processing is increased in a 
Fc!RI-dependent manner by the binding of immune complexes 7. Processed, soluble 
BAFF adopts the usual trimeric form of a TNF-family ligand, but it is the only 
member of the family that can also further assemble as an ordered, capsid-like 
structure comprising twenty trimers. The receptor-binding sites remain exposed and 
accessible at the surface of BAFF 60-mers, as shown by crystallography 8. 
Heteromers of BAFF and APRIL have also been described 4. 
 
Receptors in the BAFF system 
BAFF and APRIL both bind to the receptors B-cell maturation antigen (BCMA; also 
known as TNFRSF17) and transmembrane activator and calcium-modulator and 
cyclophilin ligand interactor (TACI; also known as TNFRSF13B), and BAFF 
additionally binds to BAFF receptor (BAFFR; also known as BR3 or TNFRSF13C) 
4, 
9
. Systematic mutagenesis studies of the relevant portions of the relatively small 
receptors TACI, BCMA and BAFFR have identified essential determinants of ligand 
binding as well as residues that account for the lack of interaction between APRIL 
and BAFFR, and for the weak binding of BAFF to BCMA 
10
 (reviewed in 
4, 9
). In 
addition to TACI and BCMA, APRIL also interacts with the polysaccharide side 
chains of heparan sulphate proteoglycans (HSPGs) (FIG 1A). This interaction is 
mediated by basic residues of APRIL and does not interfere with binding to either 
TACI or BCMA 
11, 12
. It is noteworthy that HSPG-bound APRIL is biologically active 
5, 13
. 
TACI exists as two splice variants containing a high-affinity ligand-binding 
site preceded or not by a low-affinity binding site of unknown relevance 
10
. TACI, 
similarly to APRIL, interacts with proteoglycans such as syndecans 
14
, which are 
expressed on the surface of many mesenchymal cells but also on activated 
macrophages and antibody-secreting cells. Syndecans might function as local 
activators of APRIL 
5, 13
, or as ligands that activate signalling through TACI 
14
, or as 
direct providers of signals to antibody-secreting cells 
15
. 
 Until recently, it was questionable whether the low-affinity binding of BAFF 
to BCMA was physiologically relevant. However, BCMA-dependent plasma cells in 
the bone marrow disappear if both APRIL and BAFF are removed by administration 
of TACI-Fc, but the number of these cells is not affected by selective removal of 
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either BAFF alone (by administration of BAFFR-Fc) or APRIL alone (in April-/- 
mice) 
16
, which indicates that BCMA can deliver relevant signals in response to both 
BAFF and APRIL in vivo. The weak BAFF–BCMA interaction is most probably 
stabilized by avidity effects 
17
. 
 
Signal transduction by ligand oligomerization 
A trimeric ligand such as BAFF or APRIL binds to three independent receptors to 
initiate signalling 
8, 10
. Because more than one receptor is required to transmit the 
signal, the system is susceptible to dominant effects of mutations, as is probably the 
case in patients with common variable immunodeficiency (CVID) harbouring 
heterozygous TACI mutations (Box 1) 
18, 19
. 
Binding of a trimeric ligand to its cognate receptor does not, however, 
necessarily result in productive signalling. This is particularly apparent for TACI-
dependent signals in response to APRIL stimulation in primary B cells. A single 
trimer of APRIL binds to TACI, but APRIL is essentially inactive unless it is further 
multimerized, for example by HSPG 
12, 13
. Similarly, BAFF 60-mer but not BAFF 3-
mer signals through TACI, although both forms of BAFF can initiate BAFFR-
mediated effects 
20
. These in vitro data show that signalling through TACI requires 
oligomeric ligands such as BAFF 60-mer, HSPG-bound APRIL or membrane-bound 
ligands, but not soluble, trimeric ligands. Similar conclusions were reached for TACI 
expressed by monocytes and dendritic cells 
21, 22
. The observed requirement for 
oligomeric ligands to induce signalling through TACI fits with a model in which 
intracellular signalling molecules are recruited on adjacent ligand–receptor complexes 
(FIG 1B). TNF-receptor-associated factors (TRAFs) are trimeric intracellular proteins 
that bind linear TRAF-binding sequences present in several receptors, including 
BCMA, TACI and BAFFR. The affinity of TRAFs for a monomeric receptor is very 
low, but the interaction is greatly stabilized by avidity effects when the TRAF trimer 
binds to three receptors held in the correct geometry by the ligand 
23
. TRAF2 and 
TRAF6 bind to TACI and potently activate the transcription factor nuclear factor- B 
(NF- B) if at least two trimeric TRAF molecules are held in close proximity 24, a 
situation that can be achieved when at least six receptors are recruited (FIG 1B).   The 
situation is probably different for BAFFR, which selectively recruits TRAF3 for the 
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purpose of degrading it, shortcutting the need for higher order receptor clustering to 
obtain an effect 
25-27
 (FIG 1B). 
The early steps of BAFFR signalling have long remained elusive, because 
BAFFR binds only TRAF3, which by itself does not activate the classical [G] or 
alternative NF- B pathways [G]. TRAF3 interacts with NF- B-inducing kinase 
(NIK), the upstream kinase responsible for NF- B2 processing, and induces NIK 
degradation 
28
, resulting in decreased NF- B2 activation. Targeted deletion of TRAF3 
(and/or TRAF2) in B cells leads to constitutive activation of NF- B2, recapitulating 
the effect of constant activation of BAFFR 
25
. Although TRAF2 does not interact 
directly with BAFFR, its deletion induces TRAF3 accumulation 
25
. These 
observations form the basis for a model that rationalizes the early steps of BAFFR 
signalling: in the absence of BAFF, TRAF3 binds to NIK and, with the help of 
TRAF2, induces NIK degradation by the proteasome, thus preventing activation of 
the alternative NF- B pathway. In the presence of BAFF, TRAF3 is recruited to 
BAFFR and degraded in a TRAF2-dependent manner, resulting in the stabilization of 
NIK and activation of NF- B2, which then leads to increased survival (FIG 2) 29, 30. 
 
In summary, signalling in the BAFF system is determined not only by the specificity 
of BAFF and APRIL for their respective receptors, but also by the form in which 
these ligands are presented to receptors. 
 
Expression of BAFF, APRIL and their receptors  
BAFF and APRIL are mainly produced by innate immune cells such as neutrophils, 
macrophages, monocytes, dendritic cells (DCs) and follicular dendritic cells (FDCs) 
(reviewed in 
31
), and their expression is increased by type I interferon (IFN), IFN-! , 
IL-10 and granulocyte colony-stimulating factor (G-CSF) 
31, 32
, as well as by the 
activation of Toll-like receptors (TLRs) such as TLR4 
31
 or TLR9 
33
.  T cells 
34
, 
activated B cells 
35
 and B-cell chronic lymphocytic leukaemia (B-CLL) cells can also 
produce BAFF and APRIL, contributing to tumour-cell survival in the case of B-CLL 
36
.  
 A recent development in the field is the identification of non-haematopoietic 
cells expressing BAFF and/or APRIL. These include cytotrophoblasts [G] in the 
placenta 
37
, fibroblast-like synoviocytes in the synovium of patients with rheumatoid 
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arthritis 
38
, osteoclasts in patients with multiple myeloma 
39, 40
, epithelial cells in 
tonsils 
5
 and airways 
41
, salivary gland epithelial cells in patients with Sjögren’s 
syndrome 
42
, breast adipocytes 
43
 , carcinoma cells 
43
 and astrocytes in patients with 
primary central nervous system lymphomas or multiple sclerosis 
44, 45
.  
In conclusion, activated innate immune cells and, to a lesser extent 
lymphocytes, produce BAFF and APRIL to support ongoing immune responses. 
Production of these ligands by non-haematopoietic cells might also provide local 
niches to modulate the survival and function of B cells and plasma cells in health and 
disease.   
The receptors for BAFF and APRIL are mainly expressed by B cells 
46, 47
. In 
mice, BAFFR expression is low on newly formed immature B cells, but increases as 
these cells progress through the stages of B cell maturation, and is subsequently 
expressed by all mature B cells 
46
.  TACI is expressed by all peripheral B cells and 
particularly marginal-zone [G] and B1 B cells [G] (reviewed in 48).  BCMA 
expression is restricted to antibody-producing cells 
49
.  In humans, BAFFR is widely 
expressed on B cells, except bone-marrow plasma cells 
46, 47
. TACI is expressed by 
CD27
+
 memory B cells, tonsillar and bone-marrow plasma cells, a subpopulation of 
activated CD27
-
, non-germinal-centre cells 
46, 47, 50
 and a small subset of naïve B cells 
in the blood and tonsils 
46
, which is consistent with the idea that, similar to the mouse 
system, TACI is an inducible receptor in humans. BCMA is expressed by plasma cells 
from tonsils, spleen and bone marrow 
46
, but also by tonsillar memory B cells and by 
germinal-centre B cells, the latter being TACI
–
BAFFR
low
 
47
. 
Regarding non-B cells, BAFFR expression is upregulated on T cells after 
activation 
34
 and it is constitutively expressed by regulatory T cells 
34
, whereas TACI 
is expressed by monocytes 
21
 and DCs 
22
. These results indicate that the role of BAFF 
and APRIL extends beyond that of B-cell biology, although so far little is known of 
the potential effects.  
 
The phenotype of mice deficient for BAFF, APRIL or their receptors 
In the periphery, and possibly in the bone marrow, newly formed immature B cells 
differentiate to immature transitional type 1 (T1), type 2 (T2) and/or type 3 (T3) cells 
before becoming mature follicular or marginal-zone B cells 
51
 (FIG 3).  The nature of 
the BCR decides whether a B cell becomes follicular or marginal-zone, a decision that 
is taken at the T2 stage 
52
, or even as early as the T1 stage 
53
 (FIG 3). A survival role 
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for BAFF and BAFFR during B-cell maturation was shown in BAFF- and BAFFR-
deficient animals, in which B-cell maturation is impaired beyond the T1 stage 
31
 
(Table 1).  However, B1 B cells, memory B cells and a small population of mature 
splenic B cells do not require BAFF or APRIL for survival 
16, 31, 54-56
 (FIG 3). B-cell 
maturation in April–/– mice is normal (reviewed in 4), but class switching [G] to IgA in 
two independent April–/– mouse strains is impaired 4, 57. APRIL is also important for 
the survival of class-switched mouse B cells 
58
. APRIL and BAFF mediate CD40-
independent class switching to IgA through both TACI and BAFFR 
59, 60
, and binding 
of APRIL to HSPGs might be crucial in this respect because treatment of B cells with 
heparinitase [G] abrogated the class-switching response to APRIL 15. In humans, 
intestinal epithelial cells produce APRIL in response to TLR activation, which locally 
drives TACI-mediated class switching from IgA1 to IgA2 
61
. These cells also produce 
thymic stromal lymphopoietin (TSLP) that is sensed by DCs in the lamina propria, 
which then release APRIL 
61, 62
. In the bone marrow, APRIL favours the 
establishment and/or the survival of plasmablasts, and lack of APRIL expression in 
the bone marrow of newborn mice might explain why antibody responses in neonates 
are short-lived 
58
. With time however, long-lived plasma cells accumulate to normal 
levels in APRIL-deficient mice
16, 63
, indicating a redundant role for BAFF and APRIL 
or the existence of additional trophic factors for bone marrow plasma cells.  
TACI has both positive and negative roles in the regulation of mouse B cells. 
On the one hand, TACI-deficient mice have excessive numbers of B cells, indicating 
that TACI negatively regulates the size of the B-cell compartment in vivo (reviewed 
in 
48
). On the other hand, TACI is required for efficient T-cell-independent type II 
humoral immune responses 
48
. As TACI is strongly expressed by innate B cells 
(marginal-zone and B1 cells) that are known to participate in T-cell-independent type 
II immune responses, it is probable that it provides positive signals for the maturation 
or survival of plasmablasts derived from these innate B cells 
64
. 
Bcma–/– mice are healthy, although the survival of long-lived bone-marrow 
plasma cells is impaired in these mice 
49
.  BCMA can also promote the APC function 
of B cells 
65
, although BAFF-mediated up-regulation of MHC class II expression 
through BCMA was also achieved by signalling through TACI and BAFFR 
20
. 
In summary, studies of deficient mouse strains have shown us that: BAFF and 
BAFFR control the development and survival of B2 and marginal zone B cells; 
APRIL regulates aspects of CD40-independent class switching and promotes plasma 
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cell survival; TACI helps humoral responses of innate B cells to repetitive antigens 
and somehow controls the expansion of the B cell pool; and BCMA contributes to the 
maintenance of plasma cells. B cell memory, however, does not rely on the 
BAFF/APRIL system 
16
. To what extent these findings in rodents can be extrapolated 
to humans remains to be determined.   
 
BAFF-mediated survival and growth signals in B cells 
Stimulation of BAFFR potently activates the alternative NF- B2 pathway and weakly 
activates the classical NF- B1 pathway in primary B cells, whereas TACI is a potent 
stimulator of the classical NF- B1 pathway (FIG 4) (reviewed in 48). Both NF- B 
pathways are required for B cell survival, and B cell survival can be sustained by 
signalling through BAFFR alone 
48
. TACI signalling is important for specific B cell 
types 
64
 and could also reinforce BAFFR signals, but the respective contributions of 
BAFFR and TACI to BAFF-mediated signalling have not been systematically 
addressed in the studies cited below. 
NF- B activation downstream of BAFF has been linked to increased 
expression of anti-apoptotic proteins, to integrin-mediated localization of B cells in 
the marginal zone, and to T-cell-independent antibody class switching (reviewed in 
48
). BAFF not only induces the survival of B cells, but also promotes glycolysis, 
protein synthesis and cell growth, in great part through the activation of the kinase 
mammalian target of rapamycin (mTOR) in the context of mTOR complex 1 
(mTORC1) [G] 66, 67 (FIG 4). The kinase AKT (also known as PKB) is an important 
intermediate between BAFF and mTOR. Briefly, BAFF activates phosphoinositide 3-
kinase (PI3K) through a pathway that remains to be defined. This results in the 
accumulation of the lipid phosphatidylinositol-3, 4, 5-trisphosphate (PIP3) and 
membrane recruitment of phosphoinositide-dependent protein kinase 1 (PDK1) and of 
AKT. AKT is phosphorylated at Thr308 by PDK1, and at a second activation site 
(Ser473) by protein kinase C # (PKC#) 66 and/or by mTORC2 67. Active AKT 
relieves mTORC1 inhibition. Two well-characterized targets of mTORC1 are p70-S6 
Kinase 1 (S6K1) and the eukaryotic initiation factor 4E (eIF4E) binding protein 1 
(4EBP1). Phosphorylated S6K1 activates ribosomes and increases the capacity for 
protein synthesis, whereas phosphorylated 4EBP1 releases eiF4E, which promotes 
mRNA translation 
66
. 4EBP1 is also a target of PIM2, a kinase that is induced by NF-
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 B2 68. Simultaneous inactivation of mTORC1 (with rapamycin) and PIM2 (in Pim2–
/–
 mice, which otherwise have normal B cells) rendered B cells unresponsive to BAFF 
in terms of both survival and growth, implying that these two kinases are involved in 
BAFF-mediated signals 
67
, although independent clarification of the role of PIM2 is 
required.  The effect on growth in Pim2–/– treated with rapamycin could therefore be 
explained by inefficient protein synthesis in the combined absence of PIM2 and 
mTORC1, whereas lack of survival correlates with downregulation of myeloid cell 
leukaemia sequence 1 (MCL1), as detailed below.  
MCL1 is a short-lived member of the BCL-2 family that is required for the 
development of haematopoietic stem cells and for the maintenance of peripheral B 
and T cells 
69, 70
. The PI3K–AKT pathway (downstream of BAFF) positively 
regulates transcription of the Mcl1 gene 71. In addition, active eiF4E promotes 
efficient translation of Mcl1 mRNA (as well as other mRNAs containing a GC-rich 
5’UTR) in B cells 
72
. When mTORC1 was inactivated by deletion of its positive 
regulator tuberous sclerosis protein 2 (TSC2), B-cell tumours failed to grow as a 
result of lack of MCL1 expression 
72
. In addition, MCL1-deficient B cells do not 
survive in response to BAFF 
67
, demonstrating the crucial involvement of MCL1 in 
BAFF-mediated survival. The pro-survival role of other BCL-2-family members, such 
as the NF- B targets Bcl-XL or A1 in the response to BAFF, is less clearly 
established. MCL1 acts by inhibiting the pro-apoptotic protein BIM, an essential 
mediator of B-cell death 
73
. Finally, and in agreement with the negative regulation that 
BAFF and AKT impose on glycogen synthase kinase 3# (GSK3#) and protein kinase 
C  (PKC ), these two kinases destabilize MCL1 74, 75. It is also noteworthy that both 
AKT and PIM2 inactivate the pro-apoptotic factor BAD by phosphorylation.  
MYC, by regulating the expression of numerous genes involved in 
metabolism, is also involved in the control of B-cell growth and renders B cells 
resistant to atrophy [G] 76. Interestingly, MYC is a direct target of the classical NF- B 
pathway and its expression also requires PI3K activity 
76
, providing an additional link 
between BAFF signalling and cell growth.  
In conclusion, the activation of the alternative NF- B and PI3K–AKT–mTOR 
pathways, and the upregulation of expression of Mcl1 provide a rational basis for the 
effects of BAFF on B-cell survival and metabolic fitness. 
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BAFF, APRIL and B-cell homeostasis and tolerance 
As a key survival factor for late transitional B cells 
53
, BAFF has a crucial role in B-
cell homeostasis. APRIL has no or little role in this respect: its excessive production 
leads to the development of B1 B-cell lymphomas in aging April-transgenic mice, but 
it does not cause autoimmunity and has no immediate effect on B-cell homeostasis 
(reviewed in 
4
). For reasons that are still not fully clarified, B-cell homeostasis 
depends on BAFF produced by radio-resistant cells rather than bone-marrow-derived 
cells 
55
. 
BAFFR, by transmitting survival signals, is a positive regulator of B-cell 
homeostasis, whereas signalling through TACI decreases the size of the B-cell pool. 
To do so, TACI could directly transmit inhibitory or apoptotic signals to B cells 
48, 77
, 
or it could indirectly regulate the B-cell pool by controlling the amount of BAFF that 
is available for signalling through BAFFR 
20
 or potentially the amount of TRAF 
molecules available to transmit BAFFR signals. There is also evidence that B cells 
exposed to TLR agonists upregulate BAFFR and TACI 
78
, which upon BAFF 
signalling somehow induce CD95 (FAS) expression, sensitizing B cells to CD95-
mediated killing 
79
. The relative contributions of these different pathways to the 
negative regulatory effect of TACI on the B-cell pool remain to be determined. 
In a physiological situation, strongly self-reactive B cells compete with 
‘healthy’ B cells for survival factors and for entry in the niche provided by the B-cell 
follicle in lymphoid tissue (reviewed in 
80
).  As BAFF promotes B-cell survival, its 
overexpression could potentially break B-cell tolerance by rescuing self-reactive B 
cells from deletion. However, the use of animal models mimicking the natural 
competition between healthy and self-reactive B cells has not revealed any 
catastrophic breakdown of B-cell tolerance or massive escape of high-affinity 
autoreactive B cells in Baff-transgenic mice 81, 82. In fact, strongly self-reactive B cells 
are deleted, anergized or undergo receptor editing 
1
 before they start expressing 
BAFFR on the cell surface 
82
, explaining the weak effect of BAFF on these cells. 
However, healthy B cells and low-affinity self-reactive B cells require a basal BCR 
signal to be positively selected 
83-85
. The nature of this basal BCR signal remains 
unclear but was proposed because deletion of the BCR in mature B cells led to their 
loss 
84
. [AU: the relevance of a basal BCR signal to BAFF signalling is not clear 
here]. So, the effect of excess BAFF seems to be on the positive selection and 
increased proliferation of low-affinity self-reactive B cells, mostly marginal-zone B 
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cells 
53, 82
.  In conclusion, the nature of the BCR on developing self-reactive B cells, 
the quality of its interaction with self-antigen and the need to compete with healthy B 
cells are key determinants of whether excess BAFF will allow emergence of these 
cells into the mature B cell pool 
81, 82, 86, 87
.  Current data suggest that excess BAFF 
mainly supports the survival of low-affinity self-reactive B cells. 
 
The role of BAFF in autoimmunity 
Baff-transgenic mice develop severe autoimmune symptoms that are similar to 
systemic lupus erythematosus (SLE) [G] and Sjögren’s syndrome in humans 
(reviewed in 
31
).  However, as excessive BAFF production seems to support the 
survival of low-affinity self-reactive B cells in a complex B-cell repertoire, rather than 
resulting in a breakdown of B-cell tolerance, can that event alone explain the 
devastating autoimmune disease that develops in Baff-transgenic mice?  The current 
literature on SLE agrees that the disease is mediated by several types of dysregulated 
immune cell: B cells, through autoantibody production or antigen presentation to T 
cells; innate cells such as plasmacytoid DCs, which can produce high levels of 
stimulatory cytokines such as type I IFN; and T cells, which are key players in the 
pathogenesis of SLE (reviewed in 
88, 89
).  Baff-transgenic mice have more effector T 
cells, but they also have a larger regulatory T cell compartment 
50
.  In any case, T 
cells are not responsible for the autoimmune disorder of Baff-transgenic mice, 
because autoimmunity also develops to the same extent in T-cell-deficient Baff-
transgenic mice (FIG 5), the first described animal model of T-cell-independent lupus 
50
. T-cell-independent activation of self-reactive B cells is not unique to the Baff-
transgenic model, as similar conclusions were reached in a separate mouse model of 
autoimmunity 
90
.   Collectively, these findings show that chronic activation or 
survival of T-cell-independent low-affinity self-reactive B cells by BAFF can lead to 
a form of SLE. This suggests that some patients with SLE might benefit from B-cell-
depleting or BAFF-antagonist therapies. 
 
TLR signalling promotes BAFF effects through TACI. 
In Baff-transgenic mice, B1 B-cell activity is associated with nephritis, whereas 
marginal-zone B cells might have a role in the destruction of the salivary glands but 
do not infiltrate the inflamed kidneys 91, 92.  Baff-transgenic mice lacking marginal-
zone B cells no longer developed Sjögren’s-like syndromes but they still developed 
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severe nephritis 92. However, nephritis did not develop in Baff-transgenic mice 
reconstituted with MYD88-deficient B cells 50, which indicates that activation of 
MYD88, possibly downstream of TLRs, leads to the production of pro-inflammatory 
autoantibodies that elicit complement activation and inflammation in the kidney 50 
(FIG 5). TACI might provide the link between BAFF overexpression and MYD88-
dependent activation of B cells. Indeed, activation of TLR7 and TLR9 strongly up-
regulated TACI expression 50, 78, 93, 94, a receptor that is thought to provide positive 
signals for the maturation or the survival of plasmablasts in T-cell-independent type II 
antibody responses (reviewed in 48). These results suggest a tight connection between 
TLR activation and TACI expression, which might be at the centre of the pathogenic 
mechanism in Baff-transgenic mice (FIG 5).  
In summary, the link between TLRs and TACI on B cells could be important 
for T-cell-independent antibody responses and, if dysregulated, result in SLE 
symptoms. 
 
The role of BAFF and APRIL in human diseases 
The Baff-transgenic mouse model showed a correlation between excess BAFF and 
autoimmunity (reviewed in 
31
).  Increased levels of BAFF have been measured in 
patients suffering from various autoimmune conditions and a correlation with disease 
progression has frequently been observed (reviewed in 
60
).  However, it is unclear 
whether increased levels of BAFF are a primary cause of autoimmunity or if 
autoimmunity is the result of increased production of inflammatory cytokines such as 
IFN, which are known to promote BAFF production.  The role of APRIL in human 
autoimmunity is unclear and its circulating levels do not parallel those of BAFF.   
Increased levels of BAFF and APRIL in lymphoid cancers are a well-
established observation (reviewed in 
95
).  Lymphoid cancerous cells can produce 
BAFF as an autocrine survival factor, and APRIL can have a similar role. 
Interestingly, BAFF expression has recently been detected in non-lymphoid breast 
cancer cells from epithelial origin 
43
, which indicates that the role of BAFF in cancer 
might be wider than first thought.  BAFF levels are also increased in inflammation, 
allergy and viral infection, possibly as a consequence of the production of BAFF 
inducers such as IFN.  This might, in part, explain the occasional autoimmune 
symptoms that are associated with some viral infections.  Thus, the correlation 
Mackay et al. 2009                                                                                                       Nat. Rev. Immunol. 
 
 14 
observed between dysregulation of BAFF and APRIL production and disease in 
humans has extended from autoimmunity and lymphoid cancers to other pathologies, 
and more work will be required to understand the role of BAFF and APRIL in these 
diseases. 
 
BAFF and APRIL inhibitors in the clinic: benefits and challenges. 
The relevance of BAFF in mouse models of autoimmunity, the implication of BAFF 
and/or APRIL in the survival of lymphoma cells ex vivo and the measure of increased 
BAFF levels in various pathologies has prompted several clinical trials with BAFF 
and APRIL antagonists. The most advanced clinical program is led by Human 
Genome Sciences (HGS) in partnership with Glaxo Smith Kline (GSK).  The product, 
a fully human BAFF-specific monoclonal antibody (Lymphostat-B
®
 (Belimumab)) 
96
, 
has been tested in completed phase II clinical trials in patients with rheumatoid 
arthritis and SLE 
97
.  HGS and GSK have also agreed to test Lymphostat-B in patients 
with multiple sclerosis as increased levels of BAFF have been detected in multiple-
sclerosis lesions 
44
 and recent results from a phase II clinical trial with rituximab (a 
CD20-specific B-cell-depleting antibody) indicated clinical benefits from B-cell-
specific therapies in multiple sclerosis 
98
.  
 The second program is led by ZymoGenetics Inc. in partnership with Merck-
Serono and is testing a TACI–Fc fusion protein (Atacicept), which unlike 
Lymphostat-B blocks both BAFF and APRIL 
99
. Phase II/III clinical trials are 
currently in progress for SLE, lupus nephritis, rheumatoid arthritis and relapsing 
multiple sclerosis.  Other haematological conditions are being tested in phase I 
clinical trials.  In general, Atacicept is well tolerated 
100
 and its safety profile is good.  
Atacicept seems to be particularly promising for the treatment of SLE and rheumatoid 
arthritis, and it could help patients who are not responding to TNF antagonists.    
 An important question is whether the targeting of B cells through the 
BAFF/APRIL system will be as efficient as currently approved treatments for 
rheumatoid arthritis. Indeed, TNF antagonists and CD20-specific agents have set the 
bar very high, and the lacklustre results from the Lymphostat-B phase II clinical trial 
in rheumatoid arthritis indicate that inhibition of BAFF alone might not compare 
favourably with currently used treatments for rheumatoid arthritis.  A caveat (or 
advantage) of blocking BAFF is to target mainly precursor B cell subpopulations 
rather than established antibody-producing clones or B cell memory 
56
 [AU: please 
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explain the implications of this].  Eliminating de novo production of self-reactive B 
cells is critical, yet in some disease settings elimination of established long-lived 
memory self-reactive B cells or autoantibody-producing cells may be as important. 
Another issue is the difference between human and mouse B cells in terms of the 
requirement of BAFF for survival. BAFF inhibition in non-human primates does not 
affect the survival of putative transitional B cells, is less potent at eliminating 
peripheral mature B cells, and has little effect on the survival and function of 
terminally differentiated plasma cells when compared with mice 
101, 102
.  This could 
depend on BAFF-independent B cell survival niches such as that described in the 
extravascular compartment of the bone marrow surrounding vascular sinusoids [G] 
(reviewed in 
103
). Nevertheless, it seems that use of the BAFF-specific inhibitor 
Lymphostat-B in patients with SLE might be a promising therapeutic avenue.   
Blocking BAFF, APRIL and their heteromers with Atacicept rather than with 
BAFF-specific inhibitors could have a different outcome in terms of plasma cells. 
Indeed, APRIL is implicated in plasma-cell survival and antibody production in mice 
16, 49
 and humans 
5
. In addition, mutations in both TACI alleles always result in 
antibody deficiency (Box 1), which indicates that blocking both TACI ligands might 
be more effective at eliminating antibody-producing cells in humans than are BAFF 
inhibitors or CD20-specific therapies, which are poorly efficacious on plasma cells.  
 The treatment of patients with multiple sclerosis with BAFF and/or APRIL 
inhibitors is an attractive avenue considering the potential role of B cells in some 
patients.  Moreover, currently approved IFN# treatments for multiple sclerosis and B-
cell-depleting agents in patients with autoimmune conditions are both known to 
increase serum BAFF levels 
104, 105
, raising concerns about potential B-cell-specific 
autoimmune problems associated with these treatments, and suggesting in both cases 
that combining existing treatments with BAFF inhibitors could improve the outcome.   
 
Conclusions and perspective 
The past decade of studying BAFF and APRIL has led to one of the most important 
paradigm shifts in B-cell immunology.  BAFF has emerged as a cytokine that is as 
important as the BCR in deciding the life and death of a maturing B cell, and 
important progress has been made in understanding BAFF signalling in B cells.  
Recent work has also revealed an unappreciated specific role of B cells and innate 
immune mechanisms in autoimmunity, controlled by BAFF.  The characterization of 
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different biochemical forms of BAFF and APRIL has added a new layer of signalling 
possibilities through one given receptor, in particular through TACI, which are likely 
to explain differences in receptor signalling and subsequent biology.  Finally, the 
recent realisation that BAFF, APRIL and their receptors are expressed on a wide array 
of immune and non-immune cell types is opening a new door of exciting biological 
possibilities.  Development of BAFF and/or APRIL inhibitors in the clinic is still 
strong and ongoing.  The main challenge will be to understand better the differences 
in the BAFF/APRIL system in humans compared with mice and to obtain therapeutic 
benefits superior to those of currently approved treatments.  The future might also 
show the advantage of combining existing therapies with BAFF and/or APRIL 
inhibition. 
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Box 1: TACI and BAFFR in CVID  
Common variable immunodeficiency (CVID) is characterized by a marked 
hypogammaglobulinaemia and impaired responses to vaccination, resulting in susceptibility to 
bacterial infections. CVID is diagnosed after exclusion of other causes of hypogammaglobulinemia 
and, in contrast to other primary immunodeficiencies, generally develops relatively late in life. 
About 20% of patients with CVID have signs of autoimmunity and/or lymphoproliferation 106. 
Genetic defects in the T-cell costimulatory molecule inducible T-cell costimulator (ICOS) or in the 
B-cell co-receptor CD19 are occasionally found in patients with CVID, but not as frequently as 
TACI mutations, which affect 8% of patients with CVID. Mutation of both TACI alleles is always 
associated with insufficient antibody production and, most of the time, with CVID 106. Heterozygous 
TACI mutations, in particular C104R and A181E 107, predispose to CVID rather than causing the 
disease as shown by the fact that: 2% of the control population carry a mutant TACI allele 106; 
CVID develops most of the time in the absence of TACI mutations; an heterozygous TACI 
mutation (A181E) did not segregate with disease in one familial case of CVID 106; and of two 
brothers with a homozygous TACI mutation (S144X), one was affected with CVID but the other 
had hypogammaglobulinaemia with no clinical signs of immunodeficiency, indicating that other 
genetic or environmental factors are required to induce CVID 19. Humans lacking TACI expression 
have increased numbers of B cells (as observed in Taci–/– mice), but decreased immunoglobulin 
levels (unlike Taci–/– mice), suggesting that TACI has a crucial role in immunoglobulin production 
in humans but not in mice. One patient lacking transmembrane BAFFR was reported with a severe 
B-cell lymphopaenia 108. If it can be confirmed that the mutation causes the phenotype, it could 
indicate that human B cells, similarly to mouse B cells, strongly rely on BAFF signals. 
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Figure legends 
 
FIG. 1. BAFF, APRIL and their receptors. 
A) Schematic representation of various forms of BAFF and APRIL, and their binding 
to BAFFR, TACI and BCMA. BAFF and APRIL are synthesized as membrane-bound 
proteins that can be released as soluble cytokines upon proteolytic cleavage 
(triangles). Soluble BAFF exists as homotrimers (3-mer) or as a capsid-like assembly 
of 20 trimers (60-mer). APRIL binds sulphated side chains of heparan sulphate 
proteoglycan (HSPG) at a site independent from bona fide receptor binding. TWE-
PRIL, which contains the entire receptor-binding domain of APRIL, is described as a 
membrane-bound protein only. The arrows indicate interactions that are able to 
induce signalling, although BAFF 3-mer can also bind to TACI and BCMA. The 
dashed arrow indicates a weak affinity. 
B) Model of signalling induced by BAFF 3-mer versus higher-order oligomers. 
TRAFs are trimeric intracellular signalling molecules that are recruited to three 
receptors held in the correct geometry by a trimeric ligand. Recruitment of TRAF3 to 
trimeric BAFFR leads to its degradation and releases the inhibition imposed by 
unbound TRAF3 on the alternative NF- B signalling pathway. By contrast, 
recruitment of TRAF2 or TRAF6 results in a positive signal (classical NF- B) only 
when at least two trimeric TRAFs are recruited in close proximity in response to 
higher-order oligomers of ligand, such as BAFF 60-mer or APRIL cross-linked by 
HSPG.   
 
FIG. 2.   The role of TRAF molecules in BAFFR signalling 
Left panel: In the absence of BAFF binding to BAFFR, NIK complexes with TRAF2 
and TRAF3.  TRAF2 recruits cellular inhibitor of apoptosis (c-IAP), which target 
NIK for degradation by ubiquitination.  Right panel: After BAFF binding to BAFFR, 
TRAF3 is recruited to the receptor and TRAF2 promotes TRAF3 degradation.  NIK is 
free to promote NF- B2 activation, which promotes cell survival.  
 
FIG. 3.  BAFF-dependent maturation of mouse B cells. 
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B cells develop in the bone marrow. Immature transitional type 1 (T1) B cells 
expressing a receptor lacking N regions (N
-
) (the site of random nucleotide addition at 
the V-D junction) are generated in the fetal liver or in the bone marrow and 
preferentially develop into marginal zone B cells in the spleen or B1 B cells in the 
peritoneal cavity 
109
. Some B1 B cells also home to the spleen 
110
. In the spleen, N
+
 
T1 B cells preferentially develop into mature follicular (Fo) B cells 
109
 through the 
CD21
int
 immature T2 B-cell stage, which is a precursor for both follicular and 
marginal-zone B cells 
53
. T2 cells have also been described in the bone marrow. In the 
spleen, T3 immature B cells are thought to be anergic 
111
, and a small population of 
mature CD21
low
CD23
-
IgM
+
IgD
+
 B cells survives in the absence of BAFF 
112
. A 
similar population has been described in the intestine, which in this case requires 
BAFF for survival 
113
.  B-cell subsets circled in red require BAFF for development 
and survival. 
 
FIG. 4: Signal transduction through BAFF–BAFFR 
A model of potential BAFF signalling pathways leading to B-cell survival and 
metabolic fitness. BAFF mediates B cell growth (gain of volume and protein 
synthesis, but not cell division) in part by enhancing protein translation. The mTOR 
complex 1 (mTORC1) is activated by the PI3K-AKT pathway, whereas the kinase 
PIM2 is induced by the alternative NF-kB2 pathway, although the involvement of 
PIM2 awaits confirmation in independent studies. mTORC1 and PIM2 seem to have 
redundant roles in activating translation and cell growth. MYC also promotes cell 
growth and could be at least partially under the control of BAFF through the classical 
NF- B1 pathway. In addition to cell growth, BAFF promotes B cell survival by 
favouring a high ratio of MCL1, an anti-apoptotic member of the BCL-2 family, to 
BIM, a proapoptotic antagonist of BCL-2 family members. This control is achieved at 
the transcriptional level (through CREB to enhance Mcl1, or through Fox03a to 
repress Bim) and at the translational level (through eukaryotic elongation factor 
eiF4E). The NF- B pathway also controls the expression of integrins on marginal 
zone B cells and regulates T-cell-independent isotype switching (TI switch).  See text 
for details.  
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FIG. 5: The role of excess BAFF in B-cell tolerance and activation of self-reactive B 
cells. 
Upper panel: strongly self-reactive immature T1 B cells are killed after binding to 
self-antigen before expressing sufficient BAFFR on the cell-surface and therefore 
cannot be rescued from deletion by BAFF.  By contrast, self-reactive B cells with low 
affinity for self-antigen are positively selected, acquire expression of BAFFR on the 
cell-surface, proliferate in response to increased levels of BAFF and mostly 
accumulate in the marginal-zone compartment.  Lower panel: low-affinity self-
reactive B cells, in particular marginal-zone B cells, are particularly responsive to 
Toll-like receptor (TLR) activation.  B cells expressing rheumatoid factor antibody 
can bind DNA through cell-surface immunoglobulin.  After internalisation of the 
antibody–DNA complex, the DNA can activate TLR9.  DNA-specific and RNA-
specific self-reactive B cells could therefore be activated directly through TLR9 and 
TLR7, respectively.  TACI activation up-regulates TLR expression, and TLR 
activation increases TACI expression. After TLR activation, and in the presence of 
high levels of BAFF, self-reactive B cells produce pro-inflammatory autoantibodies 
(in particular, IgG2b and IgG2c), which deposit in the kidney, and promote 
complement activation and tissue destruction. 
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Table 1: Phenotype of genetically modified mice in the BAFF/APRIL system 
 
Mouse 
model 
Phenotype References 
Ligands 
Baff-/- Impaired B-cell maturation beyond the T1 stage 
 
Decreased immunoglobulin levels; decreased T-cell-
dependent and -independent immune responses 
 
Modest increase of allograft survival, improved with a 
non-effective low dose of cyclosporin 
Reviewed 
in 
31
 
April-/- Impaired class switching to IgA 
 
Impaired tetanus-toxoid-specific plasma-cell survival in 
the bone marrow 
 
Normal survival of nitrophenol (NP)-specific bone-
marrow long-lived plasma cells 
 
Increased percentage of CD44
hi
CD62L
low
 
effector/memory T cells 
Reviewed 
in 
4
 
16, 58
 
Baff-
transgenic 
B-cell hyperplasia from the transitional type 2 B-cell 
stage 
 
T-cell-independent but MyD88-dependent 
autoimmunity: autoantibodies, glomerulonephritis, 
inflammation and destruction of the salivary glands. 
Decreased saliva production. B1 B cells in the kidney, 
Reviewed 
in 
34, 60
 
50
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marginal-zone-like B cells in the salivary glands. 
 
Expansion of the effector T-cell compartment 
 
Expansion of the regulatory T cell compartment 
April-
transgenic 
B1 B-cell neoplasia 
 
Increased survival of CD4
+
 and CD8
+
 T cells (increased 
production of IL-2 by CD8
+
 T cells) 
 
Enhanced survival of superantigen-reactive T cells 
linked to BCL-2 expression 
 
Increased T-cell proliferation 
 
Decreased percentage of T cells in peripheral lymph 
nodes. 
Reviewed 
in 
4
 
Receptors 
BaffR-/- Same as Baff-/- mice 
 
Decreased lifespan of germinal centres 
 
Impaired class-switch recombination 
114
 
A/WySnJ 
BaffR 
mutant 
Same as Baff-/- mice although less severe. 
 
Autoimmunity developing as mice age (might be 
background dependent as T cells in these mice are 
hyperresponsive to activation ex vivo). 
 
Impaired T-cell-dependent antibody responses 
 
34, 114
 
Taci-/- B-cell hyperplasia as early as the T1 B-cell stage 
 
Increased rate of B-cell proliferation 
 
Defective T-cell-independent type II antibody responses 
 
Autoimmunity, glomerulonephritis, autoantibodies 
 
B-cell lymphomas 
 
Impaired class-switch recombination to IgA 
 
Increased number of CD4
+
 T cells in Peyer’s patches 
 
Taci-/- B cells fail to induce the proliferation of antigen-
specific cytotoxic T cells after transfer to B-cell-
deficient mice. 
 
Reviewed 
in
 48
 
Bcma-/- Impaired survival of long-lived bone-marrow plasma 16, 49 
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cells. 
APRIL, a proliferation-inducing ligand; BAFF, B cell-activating factor of the 
TNF family; BAFFR, BAFF receptor; BCMA, B cell maturation antigen; IL-1, 
interleukin-1; MyD88, myeloid differentiation primary response gene 88; TACI, 
transmembrane activator and calcium-modulator and cyclophilin ligand 
(CAML) interactor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Glossary 
 
B-cell receptor editing. Process of somatic mutations that selectively alters the 
sequence and specificity of the B cell receptor. 
 
Trans-splicing. Splicing of a pre-mRNA spanning two adjacent genes.  
 
Alternative NF- B2 pathway. Signalling cascade resulting in the NF- B essential 
modulator (NEMO)-independent activation of the transcription factor NF- B. 
Hallmarks of this pathway are the implication of NF- B-inducing kinase (NIK) and 
the processing of NF- B2 from a p100 precursor to a p52 fragment.  
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Classical NF- B1 pathway. NEMO-dependent signalling pathway that activates the 
transcription factor NF- B, which usually contains the p50 subunit derived from the 
p105 NF- B1 precursor. 
 
Cytotrophoblasts. Cells of the inner layer of the trophoblast, the outermost layer in 
an embryo that serves to anchor the embryo to the maternal endometrium. 
 
Marginal-zone B cells. B cells that reside in the marginal zone, a region at the 
interface between the non-lymphoid red pulp and the lymphoid white-pulp of the 
spleen. 
 
B1 B cells. Sub-class of B cells residing predominantly in the peritoneal and pleural 
cavities, that express IgM in greater quantities than IgG and whose receptors are 
polyspecific (have low affinities for many different antigens). 
 
Class switching. The somatic-recombination process by which immunoglobulin 
isotypes are switched from IgM to IgG, IgA or IgE. This imparts flexibility to the 
humoral immune response and allows it to exploit the different capacities of these 
antibody classes to activate the appropriate downstream effector mechanisms.  
 
Heparitinase. An enzyme that catalyses the eliminative cleavage of glycosidic bonds 
in heparan sulphate. 
 
T-cell-independent type II response. Type of B cell activation in which several of 
the same antigen are presented in a way that causes cross-linking of antibodies on the 
surface of B cells, without requiring T cell help. 
 
mTORC1 complex. Multiprotein complex comprising mTOR that functions as a 
nutrient/energy/redox sensor and controls protein synthesis. The activity of this 
complex is stimulated, among others, by insulin, growth factors and amino acids. 
 
Atrophy. Cellular wasting resulting in volume loss and decreased protein content. It 
is the opposite of cell growth. 
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Systemic lupus erythematosus (SLE). An autoimmune disease in which 
autoantibodies that are specific for DNA, RNA or proteins associated with nucleic 
acids form immune complexes that damage small blood vessels, especially in the 
kidney. Patients with SLE generally have abnormal B- and T-cell function. 
 
Vascular sinusoids. Specialized blood vessels in haematopoietic tissues through 
which venous circulation occurs and that have thin walls formed by a discontinuous, 
irregularly-shaped endothelium that allows cells to pass in and out of circulation. 
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